<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366340</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-006</org_study_id>
    <nct_id>NCT00366340</nct_id>
  </id_info>
  <brief_title>Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.</brief_title>
  <official_title>A Phase 3, Randomized, Active-Controlled, Double-blind Trial of the Safety, Tolerability, and Immunologic Non-Inferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Germany.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and immunogenicity of a
      13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal conjugate
      (Prevenar/Prevenar®, 7vPnC), when given concomitantly with Infanrix hexa at 2, 3, 4, months
      (infant series) and at 11-12 months of age (toddler dose) in Germany.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series</measure>
    <time_frame>One month after 3-dose infant series (5 months of age)</time_frame>
    <description>Percentage of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series</measure>
    <time_frame>One month after 3-dose infant series (5 months of age)</time_frame>
    <description>Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC ratios (13vPnC/7vPnC) and corresponding 2-sided 95% CI were evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Antibody Titer ≥1:8 as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series.</measure>
    <time_frame>One month after 3-dose infant series (5 months of age)</time_frame>
    <description>Percentage of Participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Titer in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series</measure>
    <time_frame>One month after 3-dose infant series (5 months of age)</time_frame>
    <description>Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, and Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose</measure>
    <time_frame>One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)</time_frame>
    <description>Predefined Antibody Levels for Haemophilus Influenzae Type b (0.15 µg/mL or 1.0 µg/mL), for Diphtheria Toxoid (0.01 or 0.1 International units [IU]/mL) and for Hepatitis B (≥ 10.0 mIU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose</measure>
    <time_frame>One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration of Diphtheria Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose</measure>
    <time_frame>One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose</measure>
    <time_frame>One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)</time_frame>
    <description>Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose</measure>
    <time_frame>Immediately before (12 months of age) and one month after the toddler dose (13 months of age)</time_frame>
    <description>Antibody concentration/geometric mean concentration as measured by ELISA with their corresponding 95% CI immediately before and after the toddler dose for 7 common pneumococcal serotypes (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions</measure>
    <time_frame>Day 1 through 4 after each dose</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod)(2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)</measure>
    <time_frame>Day 1 through 4 after each dose</time_frame>
    <description>Systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)</measure>
    <time_frame>Day 1 through 4 after each dose</time_frame>
    <description>Systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">604</enrollment>
  <condition>Vaccines, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7-valent pneumococcal conjugate vaccine</intervention_name>
    <description>Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 2 months (56 to 112 days) at time of enrollment.

          2. Available for entire study period and whose parent(s) or legal guardian(s) could be
             reached by telephone.

          3. Healthy infant, as determined by medical history, physical examination, and judgment
             of the investigator.

          4. Parent(s) or legal guardian(s) had to be able to complete all relevant study
             procedures during study participation.

        Exclusion criteria:

          1. Previous vaccination with licensed or investigational pneumococcal vaccine.

          2. Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or
             hepatitis B vaccines.

          3. A previous anaphylactic reaction to any vaccine or vaccine-related component.

          4. Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis,
             polio, or hepatitis B, or pneumococcal vaccines.

          5. Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          6. Known or suspected immune deficiency or suppression.

          7. History of culture-proven invasive disease caused by S pneumoniae or H influenzae type
             b.

          8. Major known congenital malformation or serious chronic disorder.

          9. Significant neurological disorder or history of seizure, including febrile seizure, or
             significant stable or evolving disorders, such as cerebral palsy, encephalopathy,
             hydrocephalus, or other significant disorders. Did not include resolving syndromes due
             to birth trauma such as Erb palsy.

         10. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and
             monoclonal antibodies; eg, Synagis®).

         11. Participation in another investigational trial. Participation in purely observational
             studies was acceptable.

         12. Infant who was a direct descendant (eg, child or grandchild) of the study site
             personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>56 Days</minimum_age>
    <maximum_age>112 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Germany, medinfoDEU@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bad Kreuznach</city>
        <zip>55543</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Saulgau</city>
        <zip>88348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Sobernheim</city>
        <zip>55566</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13409</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birkenfeld</city>
        <zip>75217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bobingen</city>
        <zip>86399</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bramsche</city>
        <zip>49565</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bretten</city>
        <zip>75015</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cham</city>
        <zip>93413</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ehingen</city>
        <zip>89584</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91056</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eschwege</city>
        <zip>37269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gau-Odernheim</city>
        <zip>55239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herzogenaurach</city>
        <zip>91074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoechberg</city>
        <zip>97204</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kehl</city>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <zip>24111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kleve</city>
        <zip>47533</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krefeld</city>
        <zip>47798</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ludwigshafen</city>
        <zip>67059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Luebeck</city>
        <zip>23568</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metzingen</city>
        <zip>72555</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minden</city>
        <zip>32427</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenster</city>
        <zip>48159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenster</city>
        <zip>48165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neumuenster</city>
        <zip>24534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>NeumÃ¼nster</city>
        <zip>24534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neustadt/Aisch</city>
        <zip>91413</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niebuell</city>
        <zip>25899</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nuernberg</city>
        <zip>90473</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nuernberg</city>
        <zip>90482</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oberkirch</city>
        <zip>77704</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olching</city>
        <zip>82140</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pforzheim</city>
        <zip>75172</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porta Westfalica</city>
        <zip>32457</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ravensburg</city>
        <zip>88214</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tettnang</city>
        <zip>88069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vellmar</city>
        <zip>34246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weiden</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weilheim</city>
        <zip>82362</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Welzheim</city>
        <zip>73642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <zip>65205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zirndorf</city>
        <zip>90513</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2006</study_first_posted>
  <results_first_submitted>March 26, 2010</results_first_submitted>
  <results_first_submitted_qc>June 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2012</results_first_posted>
  <disposition_first_submitted>February 26, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>June 28, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 8, 2012</disposition_first_posted>
  <last_update_submitted>June 28, 2012</last_update_submitted>
  <last_update_submitted_qc>June 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>Vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in Germany from October 2006 to April 2007.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into the study according to inclusion/exclusion criteria without a screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC</title>
          <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="P2">
          <title>7vPnC</title>
          <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series) and 12 months of age (toddler dose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="296"/>
                <participants group_id="P2" count="297"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="294"/>
                <participants group_id="P2" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After the Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="287"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Parent/legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="287"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="286"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent/legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="B2">
          <title>7vPnC</title>
          <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series) and 12 months of age (toddler dose)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="301"/>
            <count group_id="B2" value="303"/>
            <count group_id="B3" value="604"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="0.6"/>
                    <measurement group_id="B2" value="2.5" spread="0.6"/>
                    <measurement group_id="B3" value="2.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series</title>
        <description>Percentage of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after 3-dose infant series (5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series) and 12 months of age (toddler dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series</title>
          <description>Percentage of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes-Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="96.0" upper_limit="99.4"/>
                    <measurement group_id="O2" value="98.2" lower_limit="95.9" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" lower_limit="72.2" upper_limit="82.2"/>
                    <measurement group_id="O2" value="87.1" lower_limit="82.5" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="96.4" upper_limit="99.6"/>
                    <measurement group_id="O2" value="96.4" lower_limit="93.5" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.9" upper_limit="99.8"/>
                    <measurement group_id="O2" value="97.5" lower_limit="94.9" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" lower_limit="94.5" upper_limit="98.8"/>
                    <measurement group_id="O2" value="98.6" lower_limit="96.3" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="92.7" upper_limit="97.8"/>
                    <measurement group_id="O2" value="96.0" lower_limit="93.0" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="84.5" upper_limit="92.2"/>
                    <measurement group_id="O2" value="89.5" lower_limit="85.3" upper_limit="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes-Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.1" lower_limit="93.2" upper_limit="98.1"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.4" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes-Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="95.9" upper_limit="99.4"/>
                    <measurement group_id="O2" value="6.3" lower_limit="3.7" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes-Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="89.3" upper_limit="95.6"/>
                    <measurement group_id="O2" value="31.6" lower_limit="25.8" upper_limit="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes-Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9" lower_limit="88.1" upper_limit="94.8"/>
                    <measurement group_id="O2" value="31.6" lower_limit="26.1" upper_limit="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes-Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="96.4" upper_limit="99.6"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes-Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="97.5" upper_limit="99.9"/>
                    <measurement group_id="O2" value="79.2" lower_limit="73.8" upper_limit="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-9.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.0</ci_lower_limit>
            <ci_upper_limit>-3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F the difference in percentages between the two groups (13vPnC - 7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lowest limit of the 2-sided 95% CI for the difference between the 2 groups &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series</title>
        <description>Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC ratios (13vPnC/7vPnC) and corresponding 2-sided 95% CI were evaluated.</description>
        <time_frame>One month after 3-dose infant series (5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series) and 12 months of age (toddler dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series</title>
          <description>Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC ratios (13vPnC/7vPnC) and corresponding 2-sided 95% CI were evaluated.</description>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" lower_limit="1.98" upper_limit="2.40"/>
                    <measurement group_id="O2" value="2.99" lower_limit="2.68" upper_limit="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.84" upper_limit="1.14"/>
                    <measurement group_id="O2" value="1.49" lower_limit="1.27" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="1.51" upper_limit="1.80"/>
                    <measurement group_id="O2" value="1.96" lower_limit="1.77" upper_limit="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" lower_limit="3.68" upper_limit="4.66"/>
                    <measurement group_id="O2" value="4.61" lower_limit="4.07" upper_limit="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" lower_limit="1.76" upper_limit="2.14"/>
                    <measurement group_id="O2" value="2.25" lower_limit="2.04" upper_limit="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.56" upper_limit="1.92"/>
                    <measurement group_id="O2" value="2.86" lower_limit="2.53" upper_limit="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="1.11" upper_limit="1.43"/>
                    <measurement group_id="O2" value="1.44" lower_limit="1.25" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" lower_limit="1.64" upper_limit="2.04"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.02" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" lower_limit="1.41" upper_limit="1.72"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" lower_limit="1.17" upper_limit="1.46"/>
                    <measurement group_id="O2" value="0.20" lower_limit="0.18" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="1.18" upper_limit="1.49"/>
                    <measurement group_id="O2" value="0.23" lower_limit="0.20" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" lower_limit="2.36" upper_limit="2.85"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" lower_limit="2.97" upper_limit="3.59"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.58" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>2.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.04</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for each common serotype was declared if the lower limit of the 2-sided 95% CI for the GMC ratio (13vPnC/7vPnC) &gt; 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Antibody Titer ≥1:8 as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series.</title>
        <description>Percentage of Participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after 3-dose infant series (5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n)=number of participants with a determinate postinfant series OPA antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series) and 12 months of age (toddler dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Titer ≥1:8 as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series.</title>
          <description>Percentage of Participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population consisting of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n)=number of participants with a determinate postinfant series OPA antibody titer to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4 (n=92,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=100,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="90.1" upper_limit="98.9"/>
                    <measurement group_id="O2" value="98.9" lower_limit="94.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=89,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=95,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n=100,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.9" lower_limit="94.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=100,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="90.1" upper_limit="98.9"/>
                    <measurement group_id="O2" value="93.6" lower_limit="86.6" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n=100,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="90.1" upper_limit="98.9"/>
                    <measurement group_id="O2" value="95.7" lower_limit="89.4" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n=100,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="86.1" upper_limit="97.1"/>
                    <measurement group_id="O2" value="4.3" lower_limit="1.2" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n=100,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="94.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="24.5" lower_limit="16.2" upper_limit="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n=100,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="94.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="4.3" lower_limit="1.2" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n=99,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="90.0" upper_limit="98.9"/>
                    <measurement group_id="O2" value="72.0" lower_limit="61.8" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n=99,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="78.7" lower_limit="69.1" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A (n=95,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="17.0" lower_limit="10.1" upper_limit="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Titer in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series</title>
        <description>Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after 3-dose infant series (5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n)= number of participants with a determinate antibody titer for the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series) and 12 months of age (toddler dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titer in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series</title>
          <description>Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n)= number of participants with a determinate antibody titer for the specified serotype.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes -Serotype 4 (n=92,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1573.29" lower_limit="1283.03" upper_limit="1929.21"/>
                    <measurement group_id="O2" value="1860.79" lower_limit="1540.00" upper_limit="2248.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=100,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="744.43" lower_limit="556.91" upper_limit="995.11"/>
                    <measurement group_id="O2" value="1160.76" lower_limit="921.46" upper_limit="1462.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=89,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4937.84" lower_limit="3614.78" upper_limit="6745.14"/>
                    <measurement group_id="O2" value="5379.51" lower_limit="3935.51" upper_limit="7353.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=95,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2139.65" lower_limit="1570.10" upper_limit="2915.79"/>
                    <measurement group_id="O2" value="3345.19" lower_limit="2473.27" upper_limit="4524.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n=100,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1509.65" lower_limit="1243.64" upper_limit="1832.56"/>
                    <measurement group_id="O2" value="1780.26" lower_limit="1382.42" upper_limit="2292.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=100,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.12" lower_limit="116.89" upper_limit="192.81"/>
                    <measurement group_id="O2" value="165.69" lower_limit="122.98" upper_limit="223.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n=100,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1089.92" lower_limit="795.20" upper_limit="1493.86"/>
                    <measurement group_id="O2" value="1070.83" lower_limit="786.59" upper_limit="1457.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n=100,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.21" lower_limit="39.39" upper_limit="64.02"/>
                    <measurement group_id="O2" value="4.15" lower_limit="3.99" upper_limit="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n=100,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.73" lower_limit="205.52" upper_limit="305.89"/>
                    <measurement group_id="O2" value="6.13" lower_limit="5.17" upper_limit="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n=100,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.02" lower_limit="126.31" upper_limit="207.82"/>
                    <measurement group_id="O2" value="4.64" lower_limit="3.96" upper_limit="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n=99,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1228.45" lower_limit="883.49" upper_limit="1708.11"/>
                    <measurement group_id="O2" value="122.40" lower_limit="74.09" upper_limit="202.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n=99,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11544.75" lower_limit="9364.02" upper_limit="14233.34"/>
                    <measurement group_id="O2" value="115.45" lower_limit="75.16" upper_limit="177.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A (n=95,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="442.48" lower_limit="360.53" upper_limit="543.06"/>
                    <measurement group_id="O2" value="6.70" lower_limit="5.19" upper_limit="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, and Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose</title>
        <description>Predefined Antibody Levels for Haemophilus Influenzae Type b (0.15 µg/mL or 1.0 µg/mL), for Diphtheria Toxoid (0.01 or 0.1 International units [IU]/mL) and for Hepatitis B (≥ 10.0 mIU/mL).</description>
        <time_frame>One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (N)= number of participants with a antibody concentration ≥ the prespecified level for the given concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age (toddler dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, and Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose</title>
          <description>Predefined Antibody Levels for Haemophilus Influenzae Type b (0.15 µg/mL or 1.0 µg/mL), for Diphtheria Toxoid (0.01 or 0.1 International units [IU]/mL) and for Hepatitis B (≥ 10.0 mIU/mL).</description>
          <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (N)= number of participants with a antibody concentration ≥ the prespecified level for the given concomitant antigen.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="252"/>
                <count group_id="O4" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Haemophilus influenzae type b 0.15 µg/mL threshold</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="85.2" upper_limit="92.9"/>
                    <measurement group_id="O2" value="86.9" lower_limit="82.1" upper_limit="90.8"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus influenzae type b 1.0 µg/mL threshold</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4" lower_limit="52.3" upper_limit="64.4"/>
                    <measurement group_id="O2" value="54.0" lower_limit="47.6" upper_limit="60.2"/>
                    <measurement group_id="O3" value="99.6" lower_limit="97.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="97.9" lower_limit="95.2" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria toxoid at 0.01 IU/mL threshold</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria toxoid at 0.1 IU/mL threshold</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" lower_limit="85.5" upper_limit="93.0"/>
                    <measurement group_id="O2" value="94.2" lower_limit="90.6" upper_limit="96.7"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B at ≥ 10.0 mIU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="91.7" upper_limit="97.2"/>
                    <measurement group_id="O2" value="96.3" lower_limit="93.2" upper_limit="98.2"/>
                    <measurement group_id="O3" value="99.3" lower_limit="97.4" upper_limit="99.9"/>
                    <measurement group_id="O4" value="98.5" lower_limit="96.1" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the difference in percentage between the two groups (13vPnC - 7vPnC) at 0.15 µg/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>8.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the difference in percentages between the two groups (13vPnC - 7vPnC) at 1.0 µg/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>13.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For diphtheria toxoid the difference in percentages between the two groups(13vPnC - 7vPnC) at 0.01 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For diphtheria toxoid the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.1 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus Influenzae Type b the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.15 µg/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For hepatitis B the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥ 10.0 mIU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the difference in percentages between the two groups (13vPnC - 7vPnC) at 1.0 µg/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For diphtheria toxoid the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.01 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For diphtheria toxoid the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.1 IU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For hepatitis B the difference in percentages between the two groups (13vPnC - 7vPnC) at ≥ 10.0 mIU/mL threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose</title>
        <time_frame>One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (N)= number of participants with a determinate antibody concentration for the specified concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC AfterToddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC AfterToddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age (toddler dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose</title>
          <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (N)= number of participants with a determinate antibody concentration for the specified concomitant antigen.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="1.03" upper_limit="1.46"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.83" upper_limit="1.20"/>
                    <measurement group_id="O3" value="11.79" lower_limit="10.36" upper_limit="13.41"/>
                    <measurement group_id="O4" value="10.24" lower_limit="8.88" upper_limit="11.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for the concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Haemophilus influenzae type b µg/mL the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for the concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration of Diphtheria Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose</title>
        <time_frame>One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (N)= number of participants with a determinate antibody concentration for the specified concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC AfterToddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC AfterToddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age (toddler dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration of Diphtheria Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose</title>
          <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (N)= number of participants with a determinate antibody concentration for the specified concomitant antigen.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="258"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" lower_limit="0.32" upper_limit="0.41"/>
                    <measurement group_id="O2" value="0.53" lower_limit="0.47" upper_limit="0.60"/>
                    <measurement group_id="O3" value="2.67" lower_limit="2.44" upper_limit="2.93"/>
                    <measurement group_id="O4" value="3.08" lower_limit="2.74" upper_limit="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For diphtheria toxoid the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for the concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For diphtheria toxoid the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for the concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose</title>
        <description>Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (N)= number of participants with a determinate antibody concentration for the specified concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC AfterToddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC AfterToddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age (toddler dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose</title>
          <description>Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (N)= number of participants with a determinate antibody concentration for the specified concomitant antigen.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="268"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.19" lower_limit="122.62" upper_limit="171.92"/>
                    <measurement group_id="O2" value="165.25" lower_limit="140.33" upper_limit="194.61"/>
                    <measurement group_id="O3" value="1118.05" lower_limit="935.26" upper_limit="1336.56"/>
                    <measurement group_id="O4" value="1195.82" lower_limit="976.12" upper_limit="1464.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For hepatitis B the GMC ratio (13vPnC/7vPnC) was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for the concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For hepatitis B the GMC ratio (13vPnC/7vPnC) was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for the concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose</title>
        <description>Antibody concentration/geometric mean concentration as measured by ELISA with their corresponding 95% CI immediately before and after the toddler dose for 7 common pneumococcal serotypes (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>Immediately before (12 months of age) and one month after the toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n)= number of participants with a determinate antibody concentration for the specified concomitant antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Before Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Before Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2, 3, 4 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age (toddler dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose</title>
          <description>Antibody concentration/geometric mean concentration as measured by ELISA with their corresponding 95% CI immediately before and after the toddler dose for 7 common pneumococcal serotypes (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population of eligible participants who adhered to protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n)= number of participants with a determinate antibody concentration for the specified concomitant antigen.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes -Serotype 4 (n=277,264,276,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="0.42" upper_limit="0.51"/>
                    <measurement group_id="O2" value="0.58" lower_limit="0.53" upper_limit="0.64"/>
                    <measurement group_id="O3" value="4.16" lower_limit="3.75" upper_limit="4.62"/>
                    <measurement group_id="O4" value="5.07" lower_limit="4.53" upper_limit="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=275,261,273,251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.87" upper_limit="1.07"/>
                    <measurement group_id="O2" value="1.06" lower_limit="0.94" upper_limit="1.20"/>
                    <measurement group_id="O3" value="9.14" lower_limit="8.14" upper_limit="10.26"/>
                    <measurement group_id="O4" value="9.85" lower_limit="8.66" upper_limit="11.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=277,265,277,262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="0.42" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.52" lower_limit="0.48" upper_limit="0.57"/>
                    <measurement group_id="O3" value="2.75" lower_limit="2.52" upper_limit="2.99"/>
                    <measurement group_id="O4" value="3.36" lower_limit="3.02" upper_limit="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=273,263,276,260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" lower_limit="1.96" upper_limit="2.48"/>
                    <measurement group_id="O2" value="2.65" lower_limit="2.34" upper_limit="3.00"/>
                    <measurement group_id="O3" value="8.34" lower_limit="7.50" upper_limit="9.28"/>
                    <measurement group_id="O4" value="11.01" lower_limit="9.87" upper_limit="12.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 18C (n=277,265,276,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.30" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.39" lower_limit="0.36" upper_limit="0.43"/>
                    <measurement group_id="O3" value="2.79" lower_limit="2.53" upper_limit="3.07"/>
                    <measurement group_id="O4" value="3.44" lower_limit="3.08" upper_limit="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 19F (n=276,264,276,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" lower_limit="0.60" upper_limit="0.76"/>
                    <measurement group_id="O2" value="0.58" lower_limit="0.52" upper_limit="0.66"/>
                    <measurement group_id="O3" value="5.99" lower_limit="5.36" upper_limit="6.68"/>
                    <measurement group_id="O4" value="4.72" lower_limit="4.12" upper_limit="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes-Serotype 23F (n=275,264,277,264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.30" upper_limit="0.37"/>
                    <measurement group_id="O2" value="0.39" lower_limit="0.34" upper_limit="0.45"/>
                    <measurement group_id="O3" value="3.36" lower_limit="2.98" upper_limit="3.78"/>
                    <measurement group_id="O4" value="4.33" lower_limit="3.75" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional - Serotype 1 (n=277,264,278,257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.48" upper_limit="0.57"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.02" upper_limit="0.03"/>
                    <measurement group_id="O3" value="4.25" lower_limit="3.80" upper_limit="4.75"/>
                    <measurement group_id="O4" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional - Serotype 3 (n=275,264,278,255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.23" upper_limit="0.28"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.05" upper_limit="0.06"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.92" upper_limit="1.13"/>
                    <measurement group_id="O4" value="0.07" lower_limit="0.06" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional - Serotype 5 (n=275,264,276,220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.67" upper_limit="0.81"/>
                    <measurement group_id="O2" value="0.34" lower_limit="0.30" upper_limit="0.39"/>
                    <measurement group_id="O3" value="3.56" lower_limit="3.25" upper_limit="3.89"/>
                    <measurement group_id="O4" value="0.51" lower_limit="0.45" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional - Serotype 6A (n=276,264,274,255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" lower_limit="0.68" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.33" lower_limit="0.29" upper_limit="0.37"/>
                    <measurement group_id="O3" value="5.88" lower_limit="5.24" upper_limit="6.59"/>
                    <measurement group_id="O4" value="1.74" lower_limit="1.51" upper_limit="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional - Serotype 7F (n=277,264,278,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.91" upper_limit="1.08"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.04" upper_limit="0.04"/>
                    <measurement group_id="O3" value="4.79" lower_limit="4.29" upper_limit="5.34"/>
                    <measurement group_id="O4" value="0.05" lower_limit="0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional - Serotype 19A (n=277,264,271,260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" lower_limit="1.14" upper_limit="1.45"/>
                    <measurement group_id="O2" value="0.72" lower_limit="0.65" upper_limit="0.80"/>
                    <measurement group_id="O3" value="9.58" lower_limit="8.68" upper_limit="10.58"/>
                    <measurement group_id="O4" value="3.79" lower_limit="3.40" upper_limit="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod)(2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Day 1 through 4 after each dose</time_frame>
        <population>Safety population, included participants who received given dose; (n) = number of participants reporting the specific characteristic.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 3 months (infant series).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 3 months (infant series).</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 4 months (infant series).</description>
          </group>
          <group group_id="O6">
            <title>7vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 4 months (infant series).</description>
          </group>
          <group group_id="O7">
            <title>13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age.</description>
          </group>
          <group group_id="O8">
            <title>7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (Mod)(2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population, included participants who received given dose; (n) = number of participants reporting the specific characteristic.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="303"/>
                <count group_id="O3" value="296"/>
                <count group_id="O4" value="297"/>
                <count group_id="O5" value="294"/>
                <count group_id="O6" value="293"/>
                <count group_id="O7" value="290"/>
                <count group_id="O8" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness-Any (n=267,267,250,241,229,221,206,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0"/>
                    <measurement group_id="O2" value="32.6"/>
                    <measurement group_id="O3" value="29.2"/>
                    <measurement group_id="O4" value="31.5"/>
                    <measurement group_id="O5" value="27.1"/>
                    <measurement group_id="O6" value="21.3"/>
                    <measurement group_id="O7" value="53.4"/>
                    <measurement group_id="O8" value="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness-Sig (n=260,258,236,226,215,209,176,158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="7.0"/>
                    <measurement group_id="O3" value="4.7"/>
                    <measurement group_id="O4" value="7.5"/>
                    <measurement group_id="O5" value="4.2"/>
                    <measurement group_id="O6" value="2.9"/>
                    <measurement group_id="O7" value="10.8"/>
                    <measurement group_id="O8" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Any (n=266,263,244,242,226,224,190,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2"/>
                    <measurement group_id="O2" value="20.5"/>
                    <measurement group_id="O3" value="26.6"/>
                    <measurement group_id="O4" value="35.1"/>
                    <measurement group_id="O5" value="26.1"/>
                    <measurement group_id="O6" value="28.6"/>
                    <measurement group_id="O7" value="36.8"/>
                    <measurement group_id="O8" value="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mild (n=265,263,243,239,226,223,186,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5"/>
                    <measurement group_id="O2" value="19.0"/>
                    <measurement group_id="O3" value="24.3"/>
                    <measurement group_id="O4" value="33.5"/>
                    <measurement group_id="O5" value="24.8"/>
                    <measurement group_id="O6" value="27.8"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mod (n=261,256,235,227,217,211,174,158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="5.9"/>
                    <measurement group_id="O3" value="7.7"/>
                    <measurement group_id="O4" value="6.6"/>
                    <measurement group_id="O5" value="6.9"/>
                    <measurement group_id="O6" value="5.2"/>
                    <measurement group_id="O7" value="12.1"/>
                    <measurement group_id="O8" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Severe(n=259,255,232,223,214,208,166,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Any (n=266,272,247,252,238,231,196,184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="34.4"/>
                    <measurement group_id="O4" value="46.8"/>
                    <measurement group_id="O5" value="34.9"/>
                    <measurement group_id="O6" value="39.8"/>
                    <measurement group_id="O7" value="47.4"/>
                    <measurement group_id="O8" value="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mild (n=265,271,247,250,237,229,191,180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="36.2"/>
                    <measurement group_id="O3" value="33.6"/>
                    <measurement group_id="O4" value="45.6"/>
                    <measurement group_id="O5" value="34.2"/>
                    <measurement group_id="O6" value="38.9"/>
                    <measurement group_id="O7" value="44.5"/>
                    <measurement group_id="O8" value="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mod (n=260,256,232,224,217,210,173,158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="1.7"/>
                    <measurement group_id="O4" value="3.6"/>
                    <measurement group_id="O5" value="4.6"/>
                    <measurement group_id="O6" value="2.4"/>
                    <measurement group_id="O7" value="11.6"/>
                    <measurement group_id="O8" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Severe (n=259,255,232,222,214,208,166,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)</title>
        <description>Systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Day 1 through 4 after each dose</time_frame>
        <population>Safety population, participants who received given dose; (n)= number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2 months (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 2 months (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 3 months (infant series).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 3 months (infant series).</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 4 months (infant series).</description>
          </group>
          <group group_id="O6">
            <title>7vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 4 months (infant series).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)</title>
          <description>Systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population, participants who received given dose; (n)= number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="303"/>
                <count group_id="O3" value="296"/>
                <count group_id="O4" value="297"/>
                <count group_id="O5" value="294"/>
                <count group_id="O6" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38°C but ≤ 39°C (n=269,266,248,250,242,232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5"/>
                    <measurement group_id="O2" value="38.7"/>
                    <measurement group_id="O3" value="46.8"/>
                    <measurement group_id="O4" value="48.4"/>
                    <measurement group_id="O5" value="46.3"/>
                    <measurement group_id="O6" value="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39°C but ≤40°C (n=260,256,238,225,216,210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="8.8"/>
                    <measurement group_id="O4" value="4.4"/>
                    <measurement group_id="O5" value="3.7"/>
                    <measurement group_id="O6" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40°C (n=259,256,233,223,216,209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased Appetite (n=269,267,249,245,236,225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1"/>
                    <measurement group_id="O2" value="30.3"/>
                    <measurement group_id="O3" value="33.7"/>
                    <measurement group_id="O4" value="34.3"/>
                    <measurement group_id="O5" value="33.1"/>
                    <measurement group_id="O6" value="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=275,266,254,252,238,235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5"/>
                    <measurement group_id="O2" value="45.1"/>
                    <measurement group_id="O3" value="47.2"/>
                    <measurement group_id="O4" value="55.2"/>
                    <measurement group_id="O5" value="45.4"/>
                    <measurement group_id="O6" value="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Sleep (n=284,272,258,256,240,241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6"/>
                    <measurement group_id="O2" value="58.8"/>
                    <measurement group_id="O3" value="53.9"/>
                    <measurement group_id="O4" value="66.8"/>
                    <measurement group_id="O5" value="49.6"/>
                    <measurement group_id="O6" value="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased Sleep (n=266,264,240,234,230,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2"/>
                    <measurement group_id="O2" value="26.1"/>
                    <measurement group_id="O3" value="23.8"/>
                    <measurement group_id="O4" value="23.1"/>
                    <measurement group_id="O5" value="20.9"/>
                    <measurement group_id="O6" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meds to Prevent Sx (n=261,262,237,234,220,220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="9.5"/>
                    <measurement group_id="O3" value="10.1"/>
                    <measurement group_id="O4" value="15.4"/>
                    <measurement group_id="O5" value="10.0"/>
                    <measurement group_id="O6" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meds to Treat Sx (n=263,266,244,235,226,225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2"/>
                    <measurement group_id="O2" value="21.1"/>
                    <measurement group_id="O3" value="28.3"/>
                    <measurement group_id="O4" value="27.2"/>
                    <measurement group_id="O5" value="20.8"/>
                    <measurement group_id="O6" value="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)</title>
        <description>Systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Day 1 through 4 after each dose</time_frame>
        <population>Safety population, participants who received given dose; (n)= number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine (Infanrix hexa) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)</title>
          <description>Systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population, participants who received given dose; (n)= number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38°C but ≤ 39°C (n=206,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7"/>
                    <measurement group_id="O2" value="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39°C but ≤40°C (n=174,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40°C (n=166,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased Appetite (n=204,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6"/>
                    <measurement group_id="O2" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=213,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4"/>
                    <measurement group_id="O2" value="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Sleep (n=202,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4"/>
                    <measurement group_id="O2" value="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased Sleep (n=195,170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication to Prevent Symptoms (n=184,182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1"/>
                    <measurement group_id="O2" value="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication to Treat Symptoms (n=178,167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>13vPnC Infant Series</title>
          <description>Participants received one single 0.5mL dose of 13vPnC coadministered with Infanrix hexa at 2, 3, 4 months. Adverse events were collected from dose 1 to approximately one month after dose 3.</description>
        </group>
        <group group_id="E2">
          <title>7vPnC Infant Series</title>
          <description>Participants received one single 0.5mL dose of 7vPnC coadministered with Infanrix hexa at 2, 3, 4 months. Adverse events were collected from dose 1 to approximately one month after dose 3.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5mL dose of 13vPnC coadministered with Infanrix hexa at 2, 3, 4 months. Adverse events were collected from approximately one month after dose 3 to toddler dose.</description>
        </group>
        <group group_id="E4">
          <title>7vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5mL dose of 7vPnC coadministered with Infanrix hexa at 2, 3, 4 months (infant series) and 12 months of age (toddler dose). Adverse events were collected from approximately one month after dose 3 to toddler dose.</description>
        </group>
        <group group_id="E5">
          <title>13vPnC Toddler Dose</title>
          <description>Participants received one single 0.5mL dose of 13vPnC at 12 months of age. Adverse events were collected for approximately one month after toddler dose.</description>
        </group>
        <group group_id="E6">
          <title>7vPnC Toddler Dose</title>
          <description>Participants received one single 0.5mL dose of 7vPnC coadministered with Infanrix hexa at 12 months of age. Adverse events were collected for approximately one month after toddler dose.</description>
        </group>
        <group group_id="E7">
          <title>13vPnC 6-Month Follow-up</title>
          <description>Participants received one single 0.5mL dose of 13vPnC coadministered with Infanrix hexa at 2, 3, 4 months (infant series) and 12 months of age (toddler dose). Adverse events were collected for approximately six months after last visit.</description>
        </group>
        <group group_id="E8">
          <title>7vPnC 6-Month Follow-up</title>
          <description>Participants received one single 0.5mL dose of 7vPnC coadministered with Infanrix hexa at 2, 3, 4 months (infant series) and 12 months of age (toddler dose). Adverse events were collected for approximately six months after last visit.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Vitello-intestinal duct remnant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Nicotine poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoeic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Local Reactions</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="220" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="152" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="143" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Mastocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dacryostenosis congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Congenital torticollis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Craniotabes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hereditary fructose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Macrocephaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Naevus flammeus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pectus excavatum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Plagiocephaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>21-hydroxylase deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Otosalpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pupils unequal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dacryoadenitis acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Eyelid disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypermetropia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dental discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Anal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Developmental delay</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever ≥38°C but ≤39°C</description>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="121" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="124" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever ≥38°C but ≤39°C</description>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever ≥38°C but ≤39°C</description>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;39°C but ≤40°C</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="174"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="157"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;39°C but ≤40°C</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt;39°C but ≤40°C</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;40°C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;40°C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt;40°C</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="89" subjects_at_risk="204"/>
                <counts group_id="E6" subjects_affected="89" subjects_at_risk="192"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Irritability</description>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="266"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="118" subjects_at_risk="213"/>
                <counts group_id="E6" subjects_affected="122" subjects_at_risk="200"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Irritability</description>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Irritability</description>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="235"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Increased sleep</description>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="114" subjects_at_risk="202"/>
                <counts group_id="E6" subjects_affected="108" subjects_at_risk="197"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Increased sleep</description>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Increased sleep</description>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="62" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="49" subjects_at_risk="170"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="234"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Atopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Candida nappy rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bacterial rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Otitis media viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pseudocroup</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Scarlet fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Sinobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Omphalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Rhinolaryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Blood immunoglobulin e increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Feeding disorder neonatal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Oral intake reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hyperphosphatasaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Posture abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Head deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypotonia neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>High-pitched crying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Myotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Fine motor delay</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pseudoparalysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Screaming</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulval disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Supraclavicular retraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Tonsillar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Eczema infantile</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Rash neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (Any)</description>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="110" subjects_at_risk="206"/>
                <counts group_id="E6" subjects_affected="96" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (Any)</description>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (Any)</description>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactionss">Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (Significant)</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="258"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="176"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="158"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (Significant)</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (Significant)</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (Any)</description>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="190"/>
                <counts group_id="E6" subjects_affected="77" subjects_at_risk="176"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (Any)</description>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="242"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (Any)</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (Mild)</description>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="62" subjects_at_risk="186"/>
                <counts group_id="E6" subjects_affected="70" subjects_at_risk="172"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (Mild)</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (Mild)</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (Moderate)</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="174"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="158"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (Moderate)</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (Moderate)</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="211"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (Any)</description>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="93" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="103" subjects_at_risk="184"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (Any)</description>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (Any)</description>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (Mild)</description>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="85" subjects_at_risk="191"/>
                <counts group_id="E6" subjects_affected="95" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (Mild)</description>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (Mild)</description>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (Moderate)</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="173"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="158"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (Moderate)</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (Moderate)</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (Severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

